Yuan Ma | Aptamer Drug | Best Researcher Award

Posted on by sciencefather

Dr. Yuan Ma | Aptamer Drug | Best Researcher Award

Dr. Yuan Ma is a Research Assistant Professor at the Hong Kong Baptist University’s School of Chinese Medicine. He holds a PhD in Pharmaceutical Sciences from Peking University, specializing in nucleic acid chemistry and drug delivery systems. His research focuses on aptamer-based translational medicine and drug discovery, with applications in cancer and bone diseases. Dr. Ma has authored over 30 publications in high-impact journals and has been recognized with awards such as the 2024 Young Scientist Award. He combines expertise in organic chemistry, pharmacology, and teaching to advance innovative therapeutic solutions.

Dr. Yuan Ma | Hong Kong Baptist University | China

Profile

SCOPUS ID

ORCID ID

🎓 Education

  • Yuan Ma completed a Bachelor of Science degree in Pharmaceutical Sciences at Peking University in 2013, majoring in Organic Chemistry, Pharmacology, and Pharmaceutical Analysis. He pursued his Master of Science degree at the same institution, focusing on DNA Synthesis, Advanced Medicinal Chemistry, and Tumor Pharmacology, culminating in 2015. In 2019, Yuan earned a Doctor of Philosophy from the Stake Key Laboratory of Natural and Biomimetic Drugs at Peking University, specializing in Nucleic Acid Chemistry, Advanced Organic Chemistry, and Natural Pharmaceutical Chemistry. Her thesis explored novel nucleoside lipid delivery mechanisms.

💼 Experience

  • Dr. Yuan Ma is currently a Research Assistant Professor at the Institute for Advancing Translational Medicine in Bone & Joint Diseases and the School of Chinese Medicine, Hong Kong Baptist University, since 2022. His previous roles include Postdoctoral Research Fellow at the same institution and Associate Research Fellow at Mengchao Hepatobiliary Hospital of Fujian Medical University. He has contributed extensively to translational research in aptamer-based drug discovery and nucleic acid-based diagnostics.

 🏆 Honors and Awards

  • Yuan has received numerous accolades, including the 2024 Young Scientist Award at the 10th International Research Awards on Genetics and Genomics of Diseases in Paris, France. He was also named Peking University Outstanding Graduate in 2019 and received the Peking University Medical Student Special Scholarship in 2017.

🛠️ Skills and Certifications

  • Dr. Yuan possesses a strong command of nucleic acid chemistry, aptamer-based drug discovery, tumor pharmacology, and advanced organic synthesis. He is also proficient in teaching and mentoring, with extensive experience lecturing at undergraduate and postgraduate levels.

🔬 Research Focus

  • Yuan Ma’s research centers on aptamer-based translational research and drug discovery, emphasizing the development of targeted therapies for cancer and bone diseases. He has advanced methodologies in nucleic acid drug development, exploring innovative strategies for improved metabolic stability, binding affinity, and therapeutic efficacy.

Conclusion

  • Dr. Yuan Ma’s work exemplifies the spirit of innovation and dedication necessary for the Best Researcher Award. His contributions to aptamer-based drug discovery and nucleic acid chemistry have not only expanded the scientific understanding of targeted therapies but also paved the way for next-generation treatments in oncology and bone health. Given his academic accomplishments, ongoing research, and the potential for significant medical breakthroughs, He is undoubtedly a leading contender for this prestigious award

📄Publications

  • Targeting osteoblastic 11β-HSD1 to combat high-fat diet-induced bone loss and obesity
    Authors: Zhong, C., Li, N., Wang, S., … Liu, J., Zhang, G.
    Journal: Nature Communications, 2024, 15(1).
  • Advancing targeted combination chemotherapy in triple negative breast cancer: nucleolin aptamer-mediated controlled drug release
    Authors: Ma, Y., Xie, D., Chen, Z., … Lu, A., Zhang, G.
    Journal: Journal of Translational Medicine, 2024, 22(1).
  • Developing Stapled Aptamers with a Constrained Conformation for Osteogenesis Imperfect Therapeutics
    Authors: Amu, G., Zhang, G., Jing, N., Ma, Y.
    Journal: Journal of Medicinal Chemistry, 2024, 67(21).
  • Aptamer functionalized hypoxia-potentiating agent and hypoxia-inducible factor inhibitor combined with hypoxia-activated prodrug for enhanced tumor therapy
    Authors: Ma, Y., Zhang, H., Shen, X., … Tang, T., Zhang, G.
    Journal: Cancer Letters, 2024, 598.
  • Sclerostin inhibition in rare bone diseases: Molecular understanding and therapeutic perspectives
    Authors: Xiaohui, T., Wang, L., Yang, X., … Zhang, Z., Zhang, G.
    Journal: Journal of Orthopaedic Translation, 2024, 47.

Xuan Zhang | Pharmacology | Best Researcher Award

Posted on by sciencefather

Prof Dr . Xuan Zhang | Pharmacology | Best Researcher Award

Patent Contributions:
  • Dr. Zhang has contributed to various patent filings, showcasing his practical contributions to drug development and medical devices. His patents, especially in areas like anti-pulmonary fibrosis drugs and innovative drug transport simulation devices, highlight his forward-thinking approach and leadership in pharmaceutical innovation
  Prof Dr. Xuan Zhang , Kunming Medical University , China

Profile

Scopus

OrcID

🎓Early Academic Pursuits

  • Xuan Zhang’s academic journey began with a Bachelor of Medicine in Clinical Medicine from Changzhi Medical University in July 2003. he further honed his expertise by obtaining a Master of Medicine in Pharmacology from Kunming Medical University in July 2006. His pursuit of knowledge continued with a Ph.D. in Cell Biology from the University of Chinese Academy of Sciences in January 2013. These academic milestones provided her with a solid foundation in pharmacology and cell biology, setting the stage for his future contributions to anti-inflammatory and immunopharmacological research.

💼Professional Endeavors

  • Dr. Xuan Zhang has had an impressive professional trajectory. he began his research career as a Research Assistant at the Yunnan Key Laboratory of Pharmacology for Natural Products, Kunming Medical University from August 2009 to July 2013. His commitment and excellence led to her appointment as an Associate Professor at the same institution, where he worked from August 2013 to September 2021. During this time, he expanded her academic horizons as a Visiting Scholar at the University of Nebraska Medical Center from January to July 2018. In October 2021, she achieved the rank of Professor at the School of Pharmaceutical Sciences & Yunnan Key Laboratory of Pharmacology for Natural Products.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS

  • Dr. Xuan Zhang’s research primarily focuses on anti-inflammatory and immunopharmacology and respiratory pharmacology. His work centers on understanding the pathogenesis and drug development for organ inflammation and fibrosis, with a special emphasis on lung-related conditions. Throughout her career, he has contributed significantly to uncovering molecular mechanisms, particularly in the context of pulmonary fibrosis and acute lung injury. His research projects, funded by prestigious organizations such as the National Natural Science Foundation of China and the Yunnan Provincial Department of Science and Technology, showcase her expertise and her leadership in exploring pharmacological interventions.

🏅ACADEMIC CITES 

  • Dr. Zhang’s academic contributions are extensively cited in the fields of pharmacology and respiratory medicine. His research has garnered attention from scholars worldwide, establishing his as a leading figure in the study of organ fibrosis. His work is continuously referenced in top journals, furthering the understanding of cell signaling pathways and inflammation management.

🏆IMPACT AND INFLUENCE

  • Dr. Zhang has completed a number of important research projects that have advanced the understanding of acute lung injury and pulmonary fibrosis, notably involving compounds like Palmatin and Gentiopicroside. These projects have yielded practical insights into therapeutic approaches, especially concerning key signaling pathways such as MAPK and NF-κB in lung injury. Moreover, his collaborative work with industry has had tangible impacts on pharmaceutical development, particularly in his consultancy projects evaluating vaccine effectiveness and the safety of novel compounds.

🧬PROFESSIONAL MEMBERSHIPS

  • Dr. Zhang is an active member of several prominent organizations, including the Chinese Pharmacological Society and the Yunnan Pharmacological Society. His roles as Deputy Secretary-General and Standing Member of these societies underline her leadership and dedication to advancing pharmacology both in China and internationally.

🔮LEGACY AND FUTURE CONTRIBUTIONS

  • Dr. Zhang’s patents, particularly in the domain of anti-pulmonary fibrosis drugs and innovative drug transport simulation devices, signify her commitment to translating research into practical applications. His continued involvement in groundbreaking research on iridoid glycosides and Geniposide is expected to yield new therapies for pulmonary fibrosis. His current projects, funded by the National Natural Science Foundation and Kunming Medical University, promise to cement his legacy as a pioneer in the field. he is also recognized as a young and middle-aged academic and technical leader in Yunnan Province, ensuring that his influence will extend to future generations of researchers.

📰PUBLICATIONS

  •  Geniposide Ameliorates Bleomycin-Induced Pulmonary Fibrosis in Mice by Inhibiting TGF-β/Smad and p38MAPK Signaling Pathways
    Authors: Yin, J.-B., Wang, Y.-X., Fan, S.-S., Zou, C., Zhang, X.
    Journal: PLoS ONE, 2024, 19(9), e0309833.
  • Mechanism of Xiyanping Injection in Treatment of Acute Lung Injury Using Network Pharmacology and Molecular Docking Analysis
    Authors: Nie, S.-Y., Fan, S.-S., Zhu, Y.-S., Wang, Y.-X., Zhang, X.
    Journal: Chinese Pharmacological Bulletin, 2024, 40(6), pp. 1165–1171.
  • Adult Pancreatoblastoma with Atypical Histological Morphology Combined with Familial Adenomatous Polyposis: A Rare Case Report
    Authors: Wang, Y.-X., Fan, S.-S., Peng, X.-R., Zhu, Y.-S., Zhang, X.
    Journal: Frontiers in Oncology, 2024, 14, 1346964.
  • Case Report: Clinicopathological Analysis of Minute Pulmonary Meningothelial-Like Nodules: Report of 7 Cases
    Authors: Wang, Y.-X., Lei, Z., Yang, M., Zhang, X., Pan, G.-Q.
    Journal: Frontiers in Oncology, 2022, 12, 942517.
  •  New 4,5-seco-20(10→5)-abeo-Abietane Diterpenoids with Anti-Inflammatory Activity from Isodon lophanthoides var. graciliflorus (Benth.) H.Hara
    Authors: Chen, W.-F., Wong, L.-L., Zhang, X., Tang, L.-P., Li, X.
    Journal: Chemistry and Biodiversity, 2019, 16(6), e1900206.